Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E NRAS G13R |
Therapy | Binimetinib + Encorafenib |
Indication/Tumor Type | melanoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E NRAS G13R | melanoma | predicted - resistant | Binimetinib + Encorafenib | Case Reports/Case Series | Actionable | In a clinical case study, NRAS G13R with progressively increasing variant allele frequency was identified in the circulating tumor DNA of a patient with metastatic melanoma harboring BRAF V600E who progressed on treatment with the combination of Mektovi (binimetinib) and Braftovi (encorafenib) (PMID: 39282524). | 39282524 |
PubMed Id | Reference Title | Details |
---|---|---|
(39282524) | Detection of multiple activating NRAS variants under BRAF/MEK-inhibitor therapy in BRAF positive malignant melanoma using liquid biopsy. | Full reference... |